At the news
? BULLISHIMPACT 6/10 PRESS-RELEASE filed Jul 8, 2026 at 17:07 ET
Rhythm Pharmaceuticals announced that the Phase 3 TRANSCEND trial results for setmelanotide (IMCIVREE) in acquired hypothalamic obesity were published in The New England Journal of Medicine. The data show a -19.8% placebo-adjusted BMI reduction with 80% of patients achieving ≥5% BMI reduction at 52 weeks. The publication reinforces the drug's efficacy after FDA approval (March 2026) and EMA recommendation, potentially supporting commercial adoption in a rare disease with no prior approved therapy.
- Placebo-adjusted BMI reduction of -19.8% (p<0.0001) in Phase 3 TRANSCEND trial
- 80% of setmelanotide-treated patients achieved ≥5% BMI reduction at 52 weeks
- Setmelanotide was generally well tolerated with no new safety signals
- FDA approval for acquired hypothalamic obesity obtained in March 2026; EMA CHMP recommended approval in March 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access